Novo Nordisk has introduced its Wegovy weight-loss pill to patients in the United Arab Emirates after the Emirates Drug Establishment granted regulatory approval earlier this week. The approval follows the product's initial release in the United States in early January and makes the UAE the second market where the oral formulation is now available.
The UAE regulator reviewed clinical evidence that supports the once-daily tablet's effectiveness in helping patients achieve weight loss and in maintaining that loss over the long term when the medication is used alongside healthy lifestyle measures. In its approval statement, the regulator also referenced data pointing to a role for the drug in lowering the risk of major adverse cardiovascular events among populations at elevated risk.
Emil Kongshoj Larsen, head of international operations at Novo Nordisk, said the company will tailor the pace and scope of additional launches to several local conditions. Specifically, future market entries will depend on patient demand, the readiness of healthcare professionals to manage obesity care with the new oral option, and whether the local health system - including telehealth services - can sustain ongoing treatment and follow-up.
"The UAE has demonstrated strong momentum across all of these areas, and we look forward to bringing Wegovy pill to additional select countries in the coming months," Larsen said.
The regulatory decision in the UAE centered on clinical outcomes observed in trials and other data reviewed by the Emirates Drug Establishment. Those data supported the tablet's capacity to contribute to weight reduction objectives and to help maintain weight outcomes when paired with lifestyle interventions. The regulator additionally highlighted evidence of reduced cardiovascular risk among at-risk groups as part of its assessment.
With the UAE now added to the list of markets offering the Wegovy pill, Novo Nordisk has signaled a measured approach to further international rollouts, linking them to measurable indicators of local readiness and demand.
Summary
Wegovy's oral tablet has been approved and launched in the UAE after regulatory clearance this week, marking the second market after the United States to offer the pill formulation. Approval was based on clinical data showing effectiveness for weight loss and maintenance, and a potential reduction in major cardiovascular events for at-risk patients. Novo Nordisk said future launches will be contingent on patient demand, healthcare professional readiness, and healthcare and telehealth capacity.